Gastrointestinal Cancer | Specialty

The gastrointestinal cancer condition center is a comprehensive resource for clinical news and expert insights on gastrointestinal cancer. Read more at OncLive.

Dr Char on the Association Between the Empirical Dietary Inflammatory Pattern and Survival Outcomes in Stage III Colon Cancer

June 1st 2025

Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.

Preoperative PAXG Extends EFS in Resectable and Borderline Resectable Pancreatic Cancer

June 1st 2025

Neoadjuvant therapy with PAXG chemotherapy prolonged event-free survival vs mFOLFIRINOX in patients with stage I to III pancreatic ductal adenocarcinoma.

Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected Esophageal/GEJ Cancer

June 1st 2025

Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.

Addition of TTFields to Gemcitabine/Nab-Paclitaxel Boosts OS in Locally Advanced PDAC

June 1st 2025

TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.

Perioperative Durvalumab Plus FLOT Represents New SOC in Resectable Gastric/GEJ Adenocarcinoma

June 1st 2025

The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.

NAPOLI-3 Analysis Exposes Characteristics of Long-Term PDAC Survivors Treated With NALIRIFOX

June 1st 2025

A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.

First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC

June 1st 2025

A fruquintinib regimen appeared safe and effective when used as a frontline treatment in esophageal squamous cell carcinoma.

Dr Picozzi on the Addition of TTFields to Gemcitabine and Nab-Paclitaxel in Locally Advanced PDAC

May 31st 2025

Vincent Picozzi, MD, discusses the addition of TFields to gemcitabine and nab-paclitaxel in locally advanced pancreatic ductal adenocarcinoma.

T-DXd Represents a New SOC in Second-Line HER2+ Gastric/GEJ Cancer

May 31st 2025

T-DXd demonstrated clinically meaningful antitumor responses as second-line treatment in HER2-positive gastric/GEJ cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025

May 30th 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Zanidatamab Wins Approval in China for Previously Treated, HER2+ Biliary Tract Cancer

May 30th 2025

China’s NMPA approved zanidatamab for previously treated, unresectable or metastatic, HER2-positive biliary tract cancer.

Neoantigen-Reactive TILs With CISH Knockout Are Safe and Effective in Metastatic GI Tumors

May 29th 2025

CRISPR-Cas9–mediated CISH gene knockout TIL therapy was well tolerated and demonstrated early signals of efficacy in metastatic GI epithelial cancer.

FDA Grants Fast Track Status to EBC-129 for Pancreatic Ductal Adenocarcinoma

May 29th 2025

EBC-129 has been awarded fast track designation from the FDA for patients with pancreatic ductal adenocarcinoma.

FOLFIRINOX Significantly Improves PFS Over Gemcitabine in Locally Advanced Pancreatic Carcinoma

May 28th 2025

NEOPAN data support the superiority of FOLFIRINOX over gemcitabine in locally advanced pancreatic carcinoma.

Later-Line Treatment Gaps in Esophageal Adenocarcinoma Underscore Need for Continued Therapeutic Development, Multidisciplinary Care

May 28th 2025

Nataliya Uboha, MD, PhD, underscores the crucial role of molecular profiling for guiding first-line treatment approaches in esophageal adenocarcinoma.

Dr Bekaii-Saab on the RATIONALE-306 Study of Tislelizumab Plus Chemotherapy in Esophageal Cancer

May 26th 2025

Tanios S. Bekaii-Saab, MD, FACP, discusses the use of tislelizumab plus chemotherapy in unresectable or metastatic ESCC.

OncLive Polls Reveal Picks for Top Gastrointestinal Cancer Abstracts at ASCO 2025

May 23rd 2025

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Gastrointestinal Cancer Experts Spotlight the Most Exciting Abstracts Ahead of the 2025 ASCO Annual Meeting

May 21st 2025

Ahead of the 2025 ASCO Annual Meeting, experts in gastrointestinal cancers provide their top anticipated studies they will be watching for at the meeting.

Dr Vonderheide on Responses With RAS(ON) Inhibition in Preclinical Pancreatic Cancer Models

May 20th 2025

Robert Herman Vonderheide, MD, DPhil, discussed potential immune responses with immunotherapy plus KRAS inhibition in pancreatic cancer models.

Dr Janjigian on Safety Considerations With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

May 19th 2025

Yelena Y. Janjigian, MD, discusses the safety of nivolumab plus chemotherapy for the first-line treatment of patients with gastric/GEJ/esophageal cancer.